Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SKYE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Formal Nasdaq notice of non-compliance with minimum bid price requirement triggers delisting risk if not cured within 180 days.
Skye Bioscience receives Nasdaq delisting warning over sub-$1 stock price
Filed March 19, 2026 · Period ending March 17, 2026 · ~1 min read
Key Changes
-
high
Nasdaq notified Skye on March 17 that its stock bid price stayed below $1.00 for 30 consecutive days, violating minimum listing requirements. The stock continues trading under SKYE while the company addresses the deficiency.
Item 3.01 verify on EDGAR → -
high
Company has until September 14, 2026 (180 days) to regain compliance by maintaining a bid price of $1.00+ for 10 consecutive business days. A reverse stock split must be completed at least 10 business days before the deadline.
Item 3.01 verify on EDGAR → -
medium
If Skye fails to comply by September, it may qualify for a second 180-day extension by meeting all other Nasdaq Capital Market standards and notifying Nasdaq of its cure plan.
Item 3.01 verify on EDGAR → -
high
Management stated it will monitor the stock price and consider options to resolve the deficiency, but provided no assurance of successful compliance or meeting other Nasdaq requirements.
Item 3.01 verify on EDGAR →
Summary
Skye Bioscience disclosed it received a deficiency notice from Nasdaq after its stock traded below $1.00 for 30 consecutive business days, violating exchange listing rules. The company has six months to fix the problem by either getting its stock price above $1.00 for at least 10 straight days or executing a reverse stock split. The stock remains listed and trading normally for now.
For retail investors, this is a significant warning sign about the company's market valuation and financial health. A sustained sub-$1 stock price often reflects investor concerns about a company's prospects. If Skye can't regain compliance, it faces potential delisting to over-the-counter markets, which typically means lower liquidity, less analyst coverage, and reduced institutional ownership.
Management acknowledged the situation but offered no specific plan or assurance of success. Watch whether Skye's stock can naturally recover above $1.00 in coming months, or whether the company announces a reverse stock split—a move that reduces share count but doesn't change underlying value and often signals continued weakness.
Section-by-Section Diff
Event · Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
If the Company does not regain compliance with Rule 5450(a) (1) by September 14, 2026, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the deficiency during the second compliance period.
If Skye fails to regain compliance by September 14, 2026, it may qualify for an additional 180-day extension. To receive this second period, the company must meet all other Nasdaq Capital Market listing standards (except bid price) and formally notify Nasdaq of its intent to cure the deficiency.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify